Table 4.

Adverse events (phase Ib cohort, n = 10).

Per person (n = 10)	Cycle 1				All cycles
	All grades	Grade 1	Grade 2	Grade 3	All grades	Grade 1	Grade 2	Grade 3
Stomatitis	6 (60.0)	4 (40.0)	2 (20.0)	0	6 (60.0)	3 (30.0)	3 (30.0)	0
Leukopenia	6 (60.0)	2 (20.0)	3 (30.0)	1 (10.0)	6 (60.0)	2 (20.0)	3 (30.0)	1 (10.0)
Neutropenia	4 (40.0)	2 (20.0)	1 (10.0)	1 (10.0)	4 (40.0)	2 (20.0)	1 (10.0)	1 (10.0)
Anemia	4 (40.0)	4 (40.0)	0	0	5 (50.0)	3 (30.0)	1 (10.0)	1 (10.0)
Skin eruption	4 (40.0)	1 (10.0)	1 (10.0)	2 (20.0)	5 (50.0)	1 (10.0)	2 (20.0)	2 (20.0)
Anorexia	3 (30.0)	2 (20.0)	1 (10.0)	0	5 (50.0)	2 (20.0)	3 (30.0)	0
Bilirubin elevation	3 (30.0)	2 (20.0)	1 (10.0)	0	3 (30.0)	2 (20.0)	1 (10.0)	0
AST/ALT elevation	3 (30.0)	2 (20.0)	0	1 (10.0)	3 (30.0)	2 (20.0)	0	1 (10.0)
Epigastric pain	2 (20.0)	2 (20.0)	0	0	2 (20.0)	2 (20.0)	0	0
Constipation	2 (20.0)	2 (20.0)	0	0	2 (20.0)	2 (20.0)	0	0
Fatigue	2 (20.0)	1 (10.0)	1 (10.0)	0	4 (40.0)	1 (10.0)	3 (30.0)	0
Myalgia	2 (20.0)	2 (20.0)	0	0	3 (30.0)	3 (30.0)	0	0
Nausea	1 (10.0)	1 (10.0)	0	0	1 (10.0)	1 (10.0)	0	0
Dyspepsia	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0
Diarrhea	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0
Fever	1 (10.0)	1 (10.0)	0	0	1 (10.0)	1 (10.0)	0	0
Peripheral neuropathy	1 (10.0)	1 (10.0)	0	0	1 (10.0)	0	1 (10.0)	0
Weight loss	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0	1 (10.0)	0
Lip edema	1 (10.0)	1 (10.0)	0	0	1 (10.0)	1 (10.0)	0	0
Throat discomfort	0	0	0	0	1 (10.0)	1 (10.0)	0	0

Data are presented as no. (%).

There was no treatment-related grade 4 adverse event.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.